Bladder Cancer Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$17995

This report covers the 8MM (US, France, Germany, Italy, Spain, UK, China, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for bladder cancer.
These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.
This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for bladder cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.
In the 8MM, the number of diagnosed incident cases of bladder cancer will grow from 279,419 cases in 2023 to 341,879 cases by 2033.
Common bladder cancer market drivers across the 8MM include:
• The sales of Padcev represent the most high-profile driver totaling $3.6 billion in 2033.
• Newly approved and pipeline agents, such as Adstiladrin, TAR200, and cretostimogene grenadenorepvec, aimed at improving outcomes for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), are key market drivers.
• Several late-stage pipeline drugs with novel MOAs have received orphan drug designation from the FDA. As such, they are granted a potential seven years of market exclusivity after approval.
Common barriers to market growth experienced across the 8MM include:
• Future patent expiry of key players, such as Keytruda and Opdivo, could introduce an influx of lower-cost and effective biosimilars, further escalating the competition in the space.
• Implementing gene therapy into a urology practice poses challenges in terms of storage and handling requirements as well as the specialized training required to administer these products.
• Higher costs of therapy for newly approved and pipeline agents will impact reimbursement in NMIBC, which has a large market size, and has traditionally been treated with low-cost chemotherapy and BCG.

Scope

Overview of bladder cancer, including epidemiology, symptoms, diagnosis, and disease management.

Annualized bladder cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the bladder cancer therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for bladder cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled.

Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

Report deliverables include a PowerPoint report and Excel-based forecast model

Forecasts includes the 8MM

Forecasts covers from 2023-2033

GlobalData valued the bladder cancer market in the 8MM at $3 billion in 2023 and expects the market to increase to $16 billion by 2033

In the base year, 2023, immunotherapy drugs contributed the highest sales, 61%, to the bladder cancer market. The current main immunotherapies used in bladder cancer are the ICIs Keytruda, Opdivo, and Bavencio, and the recently approved immunostimulant Anktiva (for NMIBC).

The class of ADCs, which includes Padcev, Enhertu, Trodelvy, and Aidix, was the second largest contributor, taking 23% of the bladder cancer market in 2023, and is expected to grow throughout the forecast period.

Gene therapy is anticipated to triple from 4% of the total market in 2023 to 12% in 2033. The rapid adoption rate of Adstiladrin and upcoming product launches are due to the drug class’s primary indication, second-line treatment in high-risk NMIBC, an area of high unmet need.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

AstraZeneca
Merck
Bristol-Myers Squibb
Gilead Sciences LLC
Roche
Pfizer
Immunomedics Inc
Astellas Pharma Co Ltd
Johnson & Johnson
Daiichi Sankyo Co Ltd
Ferring Pharmaceuticals Ltd
ImmunityBio Inc
BeiGene Ltd
Bicycle Therapeutics Inc
CG Oncology Inc
Shanghai Miracogen Inc
Fidia farmaceutici SpA
Therlase Inc
enGene Holdings Inc
UroGen Pharma Inc

Table of Contents

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

3. Disease Overview

3.1. Overview of Bladder Cancer

3.2. Bladder Cancer Market Strength, Weakness, Opportunity, and Threat Analysis

4. Epidemiology

4.1. Diagnosed Incident Cases Both Sexes

4.2. Age-Specific Diagnosed Incident Cases

4.3. Sex-Specific Diagnosed Incident Cases

4.4. Diagnosed Incident Cases by Type, Sex, Age

4.5. Diagnosed Incident Cases by Stage at Diagnosis

4.6. Diagnosed Incident Cases by Tumor Stage at Diagnosis

4.7. Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade

4.8. Diagnosed Incident Cases of Stage of Bladder Cancer by Broad Classification

4.9. Diagnosed Incident Cases of Stage of NMIBC by Risk Group

4.10. Diagnosed Incident Cases of Bladder Cancer by Mutations and Biomarkers

4.11. Five-Year Diagnosed Prevalent Cases of Bladder Cancer

4.12. Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Tumor Stage

4.13. Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Broad Classification

4.14. Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Relapse or Recurrence

4.15. Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Treatment

5. Disease Management

5.1. Treatment Guidelines

5.2. Treatment Paradigm – First-Line Therapy in Non-Muscle Invasive Bladder Cancer

5.3. Treatment Paradigm – First-Line Therapy in Muscle Invasive Bladder Cancer

5.4. Treatment Paradigm – Locally Advanced/Metastatic Bladder Cancer

5.5. KOL Insight on the Bladder Cancer Treatment Algorithm

6. Unmet Needs and Opportunities

6.1. Unmet Needs in Bladder Cancer

6.2. Unmet Needs in Bladder Cancer (2)

6.3. Unmet Needs in Bladder Cancer (3)

6.4. Unmet Needs in Bladder Cancer (4)

7. Competitive Landscape Assessment

7.1. Pipeline Drugs Overview

7.2. Competitive Landscape Methodology

7.3. Competitive Assessment – Intravesical Delivered Therapies for NMIBC

7.4. Competitive Assessment – Gene Therapies for NMIBC

7.5. Competitive Assessment – Antibody-Drug Conjugates

8. Market Outlook

8.1. Bladder Cancer Market Forecast

8.2. Bladder Cancer Market Forecast by Class

8.3. Bladder Cancer Market Drivers and Barriers

9. Appendix

9.1. Primary Research: KOL Information

9.2. Sources Used and Not Used to Forecast Diagnosed Incident Cases

9.3. Sources Used to Forecast Diagnosed Incident Cases by Stage at Diagnosis

9.4. Sources Used to Forecast Diagnosed Incident Cases by Tumor Stage at Diagnosis

9.5. Sources Used to Forecast Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade

9.6. Sources Used to Forecast Diagnosed Incident and Five-Year Diagnosed Prevalent Cases by Broad Classification

9.7. Sources Used to Forecast Diagnosed Incident Cases of NMIBC by Risk Group

9.8. Sources Used to Forecast Diagnosed Incident Cases by Mutations and Biomarkers

9.9. Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases

9.10. Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Relapse or Recurrence

9.11. Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Treatment

9.12. Sources and Methodology

9.13. Epidemiological Forecast Insight

9.14. Strengths and Limitations

9.15. About the Authors

9.16. About the Authors (2)

9.17. About the Authors (3)

9.18. About the Authors (4)

9.19. Bibliography

Bladder Cancer Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Bladder Cancer Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 in real time.

  • Access a live Bladder Cancer Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.